Looking at several waves of rise in this decade, the increase is not big, so the stock price is still hovering at a low level. This round of rise in recent months, whether it is the main hype of COVID-19 Pharmaceutical or the layout of state-owned enterprise reform (asset injection) or both, you can consider it yourself. Guangxin Group, the controlling shareholder, not only increased its holdings in the secondary market, but also actively carried out capital operation. A clear expression is to expand the scale of the company and enhance its competitiveness and profitability.
In fact, it is strengthening its controlling position. After all, Xinghu is now the only biomedical listing platform in Guangdong Province. It hasn't risen sharply in ten years. How to preserve and increase the value of state-owned assets? What are the responsibilities and faces of the pioneers of reform? Is there a great chance of grinding a sword for ten years in the end? Can there be expectations in the later period? $ Xinghu Technology (sh600866)$.